{"component": "definition", "props": {"groups": [{"size": 4, "samples": [{"hash": "5S7oQE28m9Y", "uri": "/contracts/5S7oQE28m9Y#commercialization-rights", "label": "Option and License Agreement (Zymogenetics Inc)", "score": 18.0, "published": true}, {"hash": "3faS9il8wDO", "uri": "/contracts/3faS9il8wDO#commercialization-rights", "label": "Option and License Agreement (Zymogenetics Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "right-to-conduct", "type": "clause", "offset": [15, 31]}, {"key": "clinical-development", "type": "clause", "offset": [101, 121]}, {"key": "offer-to-sell", "type": "clause", "offset": [154, 167]}, {"key": "have-sold", "type": "definition", "offset": [207, 216]}, {"key": "third-parties", "type": "definition", "offset": [448, 461]}, {"key": "marketing-agreement", "type": "definition", "offset": [478, 497]}, {"key": "strategic-partnership", "type": "definition", "offset": [499, 520]}, {"key": "joint-venture", "type": "clause", "offset": [522, 535]}, {"key": "work-on", "type": "definition", "offset": [583, 590]}, {"key": "development-of-products", "type": "clause", "offset": [604, 627]}, {"key": "right-to-sublicense", "type": "clause", "offset": [641, 660]}, {"key": "to-manufacture", "type": "definition", "offset": [687, 701]}], "snippet": "means: (a) the right to conduct -------------------------- research, use, sample, develop (including clinical development), promote, manufacture, market, offer to sell, import, export, distribute, sell, and have sold Products; and (b) the right to conduct research, use, sample, develop (including clinical development), manufacture, promote, market, offer to sell, import, export, distribute, sell and have sold Products together with one or more third parties as part of a co-marketing agreement, strategic partnership, joint venture relationship or the like in which NN continues work on research and development of Products; and (c) the right to sublicense one or more third parties to manufacture, promote, market, offer to sell, import, export, distribute, sell and have sold Products.", "hash": "f4f651b4203de5cff761bb6a166ce302", "id": 1}, {"size": 4, "samples": [{"hash": "i1Vv67Tq14G", "uri": "/contracts/i1Vv67Tq14G#commercialization-rights", "label": "Asset Purchase Agreement (Innovus Pharmaceuticals, Inc.)", "score": 24.3100616016, "published": true}, {"hash": "gK2Tzqei1BZ", "uri": "/contracts/gK2Tzqei1BZ#commercialization-rights", "label": "Asset Purchase Agreement", "score": 22.9288158795, "published": true}], "snippet_links": [{"key": "all-rights", "type": "clause", "offset": [6, 16]}, {"key": "the-intellectual-property-rights", "type": "clause", "offset": [29, 61]}, {"key": "patent-applications", "type": "definition", "offset": [72, 91]}, {"key": "trademarks-and-trademark-applications", "type": "clause", "offset": [93, 130]}, {"key": "owned-or-controlled", "type": "definition", "offset": [132, 151]}, {"key": "by-the-seller", "type": "clause", "offset": [152, 165]}, {"key": "right-to-manufacture", "type": "clause", "offset": [181, 201]}, {"key": "have-manufactured", "type": "definition", "offset": [203, 220]}, {"key": "offer-to-sell", "type": "clause", "offset": [227, 240]}, {"key": "import-and-export", "type": "clause", "offset": [248, 265]}, {"key": "regulatory-filings", "type": "definition", "offset": [280, 298]}, {"key": "marketing-materials", "type": "definition", "offset": [311, 330]}, {"key": "manufacturing-agreements", "type": "definition", "offset": [343, 367]}, {"key": "all-other-rights", "type": "clause", "offset": [372, 388]}, {"key": "to-commercialize", "type": "definition", "offset": [390, 406]}, {"key": "the-product", "type": "clause", "offset": [407, 418]}, {"key": "in-the-territory", "type": "clause", "offset": [419, 435]}], "snippet": "means all rights (other than the Intellectual Property Rights, Patents, Patent Applications, Trademarks and Trademark Applications) owned or controlled by the Seller (including the right to manufacture, have manufactured, use, offer to sell, sell, import and export including all regulatory filings, inventory, marketing materials, contracts, manufacturing agreements and all other rights) to commercialize the Product in the Territory.", "hash": "6320cbdd315e18847a8d753313f9cff8", "id": 2}, {"size": 2, "samples": [{"hash": "aKYfxyDOvzM", "uri": "/contracts/aKYfxyDOvzM#commercialization-rights", "label": "Cross License Agreement (Zymogenetics Inc)", "score": 18.0, "published": true}, {"hash": "3glJXyhi6C4", "uri": "/contracts/3glJXyhi6C4#commercialization-rights", "label": "Cross License Agreement (Zymogenetics Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "right-to-conduct", "type": "clause", "offset": [15, 31]}, {"key": "other-non", "type": "clause", "offset": [104, 113]}, {"key": "clinical-development", "type": "clause", "offset": [181, 201]}, {"key": "offer-to-sell", "type": "clause", "offset": [245, 258]}, {"key": "have-sold", "type": "definition", "offset": [298, 307]}, {"key": "third-parties", "type": "definition", "offset": [570, 583]}, {"key": "marketing-agreement", "type": "definition", "offset": [601, 620]}, {"key": "strategic-partnership", "type": "definition", "offset": [622, 643]}, {"key": "joint-venture", "type": "clause", "offset": [645, 658]}, {"key": "work-on", "type": "definition", "offset": [713, 720]}, {"key": "development-of", "type": "clause", "offset": [734, 748]}], "snippet": "means: (a) the right to conduct ------------------------ research (including research with academic and other non-profit institution collaborators), use, sample, develop (including clinical development), promote, manufacture, have made, market, offer to sell, import, export, distribute, sell, and have sold NN or ZGI Products; and (b) the right to conduct research, use, sample, develop (including clinical development), manufacture, have made, promote, market, offer to sell, import, export, distribute, sell and have sold NN or ZGI Products together with one or more third parties as part of a co- marketing agreement, strategic partnership, joint venture relationship or the like in which NN or ZGI continues work on research and development of NN or ZGI Products.", "hash": "af89e7855c0855b764ffdcfaf1405191", "id": 3}, {"size": 2, "samples": [{"hash": "acGfHOVRve7", "uri": "/contracts/acGfHOVRve7#commercialization-rights", "label": "License Agreement (Cerus Corp)", "score": 21.1889117043, "published": true}], "snippet_links": [{"key": "right-and-responsibility", "type": "clause", "offset": [67, 91]}, {"key": "pursuant-to-the", "type": "clause", "offset": [143, 158]}, {"key": "restructuring-agreement", "type": "definition", "offset": [270, 293]}, {"key": "rights-of", "type": "definition", "offset": [347, 356]}, {"key": "concurrent-agreements", "type": "definition", "offset": [401, 422]}, {"key": "upon-termination-of", "type": "clause", "offset": [423, 442]}, {"key": "for-the-purposes-of-this-agreement", "type": "clause", "offset": [504, 538]}, {"key": "references-to-termination", "type": "clause", "offset": [540, 565]}, {"key": "licenses-and-related-rights", "type": "clause", "offset": [693, 720]}, {"key": "pursuant-to-section-4", "type": "clause", "offset": [766, 787]}, {"key": "agreement-or", "type": "definition", "offset": [839, 851]}, {"key": "the-case", "type": "definition", "offset": [877, 885]}], "snippet": "means, as to a particular country or region, (a) as to Baxter, the right and responsibility to market, distribute and sell the Platelet System pursuant to the Platelet Agreement, and the Plasma System pursuant to the RBC/FFP Agreement (and as further provided under the Restructuring Agreement), in that country or region; or (b) as to Cerus, all rights of Cerus under the Restructuring Agreement and Concurrent Agreements upon termination of \u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 Commercialization rights in that country or region. For the purposes of this agreement, references to termination of Baxter Commercialization Rights, or to Cerus gaining Commercialization Rights, in a particular country or region means that licenses and related rights have been released and relinquished to Cerus pursuant to Section 4 of the Restructuring Agreement, under the Platelet Agreement or the RBC/FFP Agreement as the case may be.", "hash": "f0df6a4d551210cdb576dd27b56ff8a0", "id": 4}, {"size": 1, "samples": [{"hash": "1mf3jKNeHq8", "uri": "/contracts/1mf3jKNeHq8#commercialization-rights", "label": "License Agreement (Zymogenetics Inc)", "score": 21.1615331964, "published": true}], "snippet_links": [{"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [22, 60]}, {"key": "right-to-make", "type": "clause", "offset": [79, 92]}, {"key": "an-election", "type": "clause", "offset": [93, 104]}, {"key": "right-to-conduct", "type": "clause", "offset": [125, 141]}, {"key": "clinical-development", "type": "clause", "offset": [184, 204]}, {"key": "offer-to-sell", "type": "clause", "offset": [237, 250]}, {"key": "have-sold", "type": "definition", "offset": [290, 299]}, {"key": "contract-research", "type": "clause", "offset": [333, 350]}, {"key": "third-parties", "type": "definition", "offset": [587, 600]}, {"key": "marketing-agreement", "type": "definition", "offset": [617, 636]}, {"key": "strategic-partnership", "type": "definition", "offset": [638, 659]}, {"key": "joint-venture", "type": "clause", "offset": [661, 674]}, {"key": "work-on", "type": "definition", "offset": [739, 746]}, {"key": "development-of-products", "type": "clause", "offset": [760, 783]}, {"key": "right-to-sublicense", "type": "clause", "offset": [797, 816]}, {"key": "to-manufacture", "type": "definition", "offset": [843, 857]}], "snippet": "means, subject to the terms and conditions of this Agreement, including ZGEN\u2019s right to make an Election to Co-Fund: (a) the right to conduct research, use, sample, develop (including clinical development), manufacture, promote, market, offer to sell, import, export, distribute, sell, and have sold Products, including the use of , contract research organizations; and (b) the right to conduct research, use, sample, develop (including clinical development), manufacture, promote, market, offer to sell, import, export, distribute, sell and have sold Products together with one or more third parties as part of a co-marketing agreement, strategic partnership, joint venture relationship or the like in which NN or its Affiliate continues work on research and development of Products; and (c) the right to sublicense one or more third parties to manufacture, promote, market, offer to sell, import, export, distribute, sell or have sold Products.", "hash": "49729c470ea74932c3e3ac2108343b2b", "id": 5}, {"size": 1, "samples": [{"hash": "5SShl6vQGpM", "uri": "/contracts/5SShl6vQGpM#commercialization-rights", "label": "Cross License Agreement (Micromet, Inc.)", "score": 21.0, "published": true}], "snippet_links": [{"key": "the-right", "type": "clause", "offset": [6, 15]}], "snippet": "means the right or option (whether or not ultimately exercised) to market, co-market, promote, co-promote or sell a product.", "hash": "dc4ac3e5130046cf0666ececb5bbe171", "id": 6}, {"size": 1, "samples": [{"hash": "2KuRnu1IJ1v", "uri": "/contracts/2KuRnu1IJ1v#commercialization-rights", "label": "Cross License Agreement (Zymogenetics Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "right-to-conduct", "type": "clause", "offset": [15, 31]}, {"key": "other-non", "type": "clause", "offset": [106, 115]}, {"key": "clinical-development", "type": "clause", "offset": [183, 203]}, {"key": "offer-to-sell", "type": "clause", "offset": [236, 249]}, {"key": "have-sold", "type": "definition", "offset": [289, 298]}, {"key": "third-parties", "type": "definition", "offset": [530, 543]}, {"key": "marketing-agreement", "type": "definition", "offset": [560, 579]}, {"key": "strategic-partnership", "type": "definition", "offset": [581, 602]}, {"key": "joint-venture", "type": "clause", "offset": [604, 617]}, {"key": "work-on", "type": "definition", "offset": [672, 679]}, {"key": "development-of-products", "type": "clause", "offset": [693, 716]}, {"key": "right-to-sublicense", "type": "clause", "offset": [730, 749]}, {"key": "to-manufacture", "type": "definition", "offset": [776, 790]}], "snippet": "means: (a) the right to conduct -------------------------- research (including research with academic and other non-profit institution collaborators), use, sample, develop (including clinical development), promote, manufacture, market, offer to sell, import, export, distribute, sell, and have sold products; and (b) the right to conduct research, use, sample, develop (including clinical development), manufacture, promote, market, offer to sell, import, export, distribute, sell and have sold products together with one or more third parties as part of a co-marketing agreement, strategic partnership, joint venture relationship or the like in which NN or ZGI continues work on research and development of products; and (c) the right to sublicense one or more third parties to manufacture, promote, market, offer to sell, import, export, distribute, sell and have sold products.", "hash": "2b948a63f6c6e8cba18afdebc3f81cfa", "id": 7}, {"size": 1, "samples": [{"hash": "ckt33fFk007", "uri": "/contracts/ckt33fFk007#commercialization-rights", "label": "Restructuring Agreement (Cerus Corp)", "score": 21.1889117043, "published": true}], "snippet_links": [{"key": "responsibility-of", "type": "clause", "offset": [77, 94]}, {"key": "settlement-agreement", "type": "clause", "offset": [135, 155]}, {"key": "pursuant-to-the", "type": "clause", "offset": [204, 219]}, {"key": "rights-of", "type": "definition", "offset": [395, 404]}, {"key": "concurrent-agreements", "type": "definition", "offset": [435, 456]}, {"key": "upon-termination-of", "type": "clause", "offset": [457, 476]}, {"key": "for-the-purposes-of-this-agreement", "type": "clause", "offset": [538, 572]}, {"key": "references-to-termination", "type": "clause", "offset": [574, 599]}, {"key": "licenses-and-related-rights", "type": "clause", "offset": [727, 754]}, {"key": "agreement-or", "type": "definition", "offset": [774, 786]}, {"key": "the-case", "type": "definition", "offset": [813, 821]}, {"key": "pursuant-to-section-4", "type": "clause", "offset": [876, 897]}, {"key": "restructuring-agreement", "type": "definition", "offset": [906, 929]}], "snippet": "means, as to a particular country or region, (a) as to Baxter, the right and responsibility of Baxter to EXECUTION 1 RESTRUCTURING AND SETTLEMENT AGREEMENT market, distribute and sell the Platelet System pursuant to the Platelet Agreement, and the Plasma System pursuant to the RBC/FFP Agreement (and as further provided under this Agreement), in that country or region; or (b) as to Cerus, all rights of Cerus hereunder and under the Concurrent Agreements upon termination of \u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 Commercialization rights in that country or region. For the purposes of this agreement, references to termination of Baxter Commercialization Rights, or to Cerus gaining Commercialization Rights, in a particular country or region means that licenses and related rights under the Platelet Agreement or the RBC/FFP Agreement, as the case may be, have been released and relinquished to Cerus, pursuant to Section 4 of this Restructuring Agreement;", "hash": "5e5a7abcad3fa66e6f74a2d7835557ef", "id": 8}, {"size": 1, "samples": [{"hash": "aSVTgpiNYpj", "uri": "/contracts/aSVTgpiNYpj#commercialization-rights", "label": "Asset Purchase Agreement (Apricus Biosciences, Inc.)", "score": 24.2470910335, "published": true}], "snippet_links": [{"key": "filings-and-authorizations", "type": "clause", "offset": [21, 47]}, {"key": "related-information", "type": "definition", "offset": [57, 76]}, {"key": "other-items", "type": "clause", "offset": [81, 92]}, {"key": "exhibit-a", "type": "clause", "offset": [103, 112]}], "snippet": "means all regulatory filings and authorizations, Product-related information and other items listed in Exhibit A hereto under the heading \u201cCommercialization Rights.\u201d", "hash": "b5a91b218531b8b88f20b5fbd92e8e78", "id": 9}, {"size": 1, "samples": [{"hash": "2Odi33wJixc", "uri": "/contracts/2Odi33wJixc#commercialization-rights", "label": "Manufacturing Agreement (Wex Pharmaceuticals Inc.)", "score": 21.0, "published": true}], "snippet_links": [{"key": "further-defined", "type": "clause", "offset": [72, 87]}], "snippet": "shall have the meaning ascribed to this term in Subsection 9.1.1 and as further defined in Subsection 9.1.2;", "hash": "19f1a2089613a00181d6cbafb116c63a", "id": 10}], "next_curs": "CmUSX2oVc35sYXdpbnNpZGVyY29udHJhY3RzckELEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIhY29tbWVyY2lhbGl6YXRpb24tcmlnaHRzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 22, "snippet": "means: (a) the right to conduct -------------------------- research, use, sample, develop (including clinical development), promote, manufacture, market, offer to sell, import, export, distribute, sell, and have sold Products; and (b) the right to conduct research, use, sample, develop (including clinical development), manufacture, promote, market, offer to sell, import, export, distribute, sell and have sold Products together with one or more third parties as part of a co-marketing agreement, strategic partnership, joint venture relationship or the like in which NN continues work on research and development of Products; and (c) the right to sublicense one or more third parties to manufacture, promote, market, offer to sell, import, export, distribute, sell and have sold Products.", "title": "Commercialization Rights", "id": "commercialization-rights", "examples": ["Unless, before the expiration or termination -------- of the Option Period for a given ZSS, NN exercises the RoW Option for such ZSS (pursuant to SECTION 4.2), all <strong>Commercialization Rights</strong>, in RoW, in all fields, for Products based on Zid Embodiments in such ZSS shall revert to ZGI.", "The arbitrator shall select the proposal which most closely reflects fair value of the PRC <strong>Commercialization Rights</strong>.", "Similarly, unless, before the expiration or termination of the Option Period for a given ZSS, NN exercises the BC Option for such ZSS (pursuant to SECTION 4.2), all <strong>Commercialization Rights</strong> worldwide in the BC Field, for Products based on Zid Embodiments in such ZSS shall revert to ZGI.", "ALMIRALL wishes to \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587 and, ASLAN wishes to receive from ALMIRALL, a license to use the ALMIRALL Information with the exclusive purpose of conducting the Development and, after that, to exercise ASLAN\u2019s <strong>Commercialization Rights</strong> on the terms and conditions set forth in this Agreement.", "Upon entering this Agreement, ASLAN shall be granted ASLAN\u2019s <strong>Commercialization Rights</strong>.", "Upon completion of the Development Plan, the Parties shall meet through the JSC in order to inform ALMIRALL of any additional regulatory documents and proceedings will be necessary, if any, to be prepared and filled, in order to continue with the development of the Product or for ASLAN to exercise ASLAN\u2019s <strong>Commercialization Rights</strong>.", "As provided in Section 2.1 above, ALMIRALL grants ASLAN the exclusive and non-assignable right to use the ALMIRALL IP in the Territory and during the Term, with the purpose of manufacturing the Product to conduct the Development and exercising ASLAN\u2019s <strong>Commercialization Rights</strong>.", "It shall be a condition to exercise of \u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 options to extend any <strong>Commercialization Rights</strong> into any Extension Period that Baxter shall be in compliance, in all material respects, with the requirements of this Agreement, the Platelet Agreement, the RBC/FFP Agreement (as to Plasma System matters) and the Concurrent Agreements at the time of such exercise.", "For ZGI Patents and NN Patents that were the --------- subject of an agreement between NN and [ * ] dated July 18, 1996, any commercialization license granted pursuant to SUBSECTION 4.3.1 above shall not include <strong>Commercialization Rights</strong> for [ * ].", "If NN exercises a RoW Option and enters into a PLPC RoW License for a given ZSS, for a period of [*] after such exercise (&quot;BC Grace Period at PLPC&quot;), ZGI shall not enter into any agreement nor offer to enter any agreement, with any third party, which grants any <strong>Commercialization Rights</strong> for Products in the BC Field for that ZSS."], "related": [["commercialization", "Commercialization", "Commercialization"], ["commercialization-plan", "Commercialization Plan", "Commercialization Plan"], ["licensed-program", "Licensed Program", "Licensed Program"], ["development-rights", "Development rights", "Development rights"], ["development-program", "Development Program", "Development Program"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}